Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7336 to 7350 of 7675 results

  1. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Technology appraisal guidance
    Published
    23 January 2019

  2. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Technology appraisal guidance
    Published
    20 November 2019

  3. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Technology appraisal guidance
    Published
    27 November 2013

  4. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development [GID-TA10905] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

    Technology appraisal guidance
    Published
    4 January 2023

  7. Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    20 January 2015

  8. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    In development [GID-TA10926] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Meningitis (bacterial) and meningococcal septicaemia in children and young people (QS19)

    March 2024: We have temporarily withdrawn this quality standard due to the update to the NICE guideline on meningitis, which underpins the quality statements. 

    See the quality standard in development page. for progress on this update.

    Quality standard
    Published
    27 June 2012

  10. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)

    This guideline has been updated and replaced by NICE guideline NG240.

    Clinical guideline
    Last updated
    1 February 2015

  11. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Technology appraisal guidance
    Published
    28 August 2019

  13. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    21 February 2017

  14. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019

  15. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    21 March 2017